J-shaped association between fasting blood glucose levels and COVID-19 severity in patients without diabetes

Abstract

Coronavirus disease 2019 (COVID-19) has become a recognized worldwide pandemic. Researchers now know that mortality from COVID-19 can be reduced through early prevention measures. This retrospective, multi-centered study of 293 COVID-19 patients without diabetes explores the association between fasting blood glucose (FBG) levels and the risk of COVID-19 disease progression, with the goal of providing clinical evidence for glycemic targets in patients. Methods: The multivariate stepwise binary logistic regression analysis was used to test the dose-response effects of FBG levels on the risk of severe and critical condition in COVID-19 patients.

Biomarkers associated with coronavirus disease-19 disease progression in a Mexican hospital

“…It is also relevant to note that there exist multiple factors that may elevate levels of LDH; thus, this variable must be considered in the individual context of the patient to be able to use it to establish a prognostic profile. Glucose level was useful to predict disease progression not considering if the patients were previously diabetic and above other biomarkers, this result is consistent with other cohorts 21 . Biomarkers such as IL-6, the NLR, and the LPR did not demonstrate statistical significance in our analysis toward the creation of a prognostic profile and the demonstration of an increment in mortality nor complications.…”

Hyperglycemia is Associated With Increased Mortality in Critically Ill Patients With COVID-19

“…Zhu and colleagues provided data suggesting that maintaining euglycemia (70-180 mg/dL) in patients with type 2 DM reduced the occurrence of death, acute respiratory distress syndrome, septic shock, acute kidney injury, and renal-replacement therapy in a cohort of hospitalized patients in China ( 1 ). A number of other studies have also associated hyperglycemia with worse outcomes in hospitalized patients with COVID-19 ( 5 , 6 , 7 ). However, these studies have analyzed these questions in hospitalized populations predominantly outside of the intensive-care unit (ICU), and the impact of hyperglycemia on mortality in critically ill patients with and without pre-existing DM in the setting of COVID-19 remains unclear ( 8 ).…”

High admission blood glucose independently predicts poor prognosis in COVID-19 patients: A systematic review and dose-response meta-analysis

“…DRMA for severity outcome consisted of three studies [32,39,40] Figure 4B) across the range between 4.5 mmol/L and 14.1 mmol/L. Moreover, we observed a non-linear relationship (P non-linearity <0.001), where the risks of progression to severe COVID-19 cases decelerated starting from 6.6 mmol/L and re-exponentiated starting from admission FBG level of 8.1 mmol/L ( Figure 4C).…”